Decades of History Tell Anything: Biotech Near $50 Set to Soar
A cash-generative biotech near $50 is drawing buyers amid a market shift toward defensible healthcare names. Here’s w...
Identify the best retirement plan tailored to your needs. Make informed decisions for a secure financial future.
20,379 articlesA cash-generative biotech near $50 is drawing buyers amid a market shift toward defensible healthcare names. Here’s w...
A fast-growing Brazilian fintech is reshaping personal finance in Latin America. Here are three concrete reasons this...
A top psychologist says the decade-long drop in U.S. reading scores isn’t caused by immigration, but by pervasive dev...
A trader alleges Polymarket unfairly resolved a market tied to MicroStrategy's bitcoin sale, claiming a post-deadline...
As bond markets evolve, a widely used bond ETF faces renewed scrutiny over cost and hedging power. Investors are aske...
Anthropic's public listing signals a new wave of AI investment. This piece highlights which major tech names could ri...
As bond markets flash warnings and oil risk climbs from Gulf tensions, a leading wall street strategist warns that th...
Ripple’s latest briefing argues passive Zcash holders remain protected if they did not trigger the exploit, even as m...
A Perdoceo director recently exercised 9,308 options and sold shares, triggering questions for investors. This guide ...
Chip stocks lead a cautious rebound as SpaceX prepares for an IPO, lifting the Nasdaq Composite in early trading whil...
A new income-focused ETF challenger has pushed past JEPI by roughly 42 percentage points since its October 2023 debut...
With the MiCA grace period ending on July 1, 2026, thousands of platforms face closure or forced transfers. Millions ...